Key Points
- Insider sale: Abeona insider Madhav Vasanthavada sold 12,610 shares at an average price of $5.29 on Jan. 22 for a total of $66,706.90, trimming his position by 3.81% to 318,619 shares (about $1.685M), per an SEC filing.
- Stock snapshot and analyst view: ABEO trades around $5.19 with a $281.25M market cap, P/E of 4.22 and a 52‑week range of $3.93–$7.54; analysts are mixed but show a consensus price target of $20.
- Heavy institutional ownership: About 80.56% of shares are held by hedge funds and institutions, including Goldman Sachs which boosted its stake by 49.6% to 200,450 shares.
Abeona Therapeutics Inc. (NASDAQ:ABEO - Get Free Report) insider Madhav Vasanthavada sold 12,610 shares of the stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $5.29, for a total value of $66,706.90. Following the completion of the transaction, the insider directly owned 318,619 shares in the company, valued at $1,685,494.51. This trade represents a 3.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Abeona Therapeutics Price Performance
ABEO stock opened at $5.19 on Tuesday. The business has a 50 day moving average price of $5.10 and a 200 day moving average price of $5.63. The stock has a market cap of $281.25 million, a price-to-earnings ratio of 4.22 and a beta of 1.12. Abeona Therapeutics Inc. has a fifty-two week low of $3.93 and a fifty-two week high of $7.54. The company has a quick ratio of 9.53, a current ratio of 9.74 and a debt-to-equity ratio of 0.06.
Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last announced its quarterly earnings results on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.17. Equities research analysts anticipate that Abeona Therapeutics Inc. will post -1.16 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on ABEO shares. Wall Street Zen cut shares of Abeona Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, November 15th. HC Wainwright reiterated a "buy" rating and set a $20.00 target price on shares of Abeona Therapeutics in a research report on Monday, October 13th. Finally, Weiss Ratings reissued a "sell (d+)" rating on shares of Abeona Therapeutics in a research report on Wednesday, January 21st. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Abeona Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $20.00.
Get Our Latest Stock Report on Abeona Therapeutics
Institutional Investors Weigh In On Abeona Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in ABEO. Goldman Sachs Group Inc. boosted its stake in shares of Abeona Therapeutics by 49.6% during the first quarter. Goldman Sachs Group Inc. now owns 200,450 shares of the biopharmaceutical company's stock worth $954,000 after buying an additional 66,422 shares during the period. Riverwater Partners LLC purchased a new stake in Abeona Therapeutics during the 2nd quarter valued at approximately $62,000. Y Intercept Hong Kong Ltd purchased a new stake in Abeona Therapeutics during the 2nd quarter valued at approximately $581,000. Los Angeles Capital Management LLC acquired a new stake in Abeona Therapeutics during the 2nd quarter worth approximately $1,523,000. Finally, Simplify Asset Management Inc. grew its stake in shares of Abeona Therapeutics by 36.7% in the 2nd quarter. Simplify Asset Management Inc. now owns 558,584 shares of the biopharmaceutical company's stock valued at $3,173,000 after purchasing an additional 150,000 shares during the last quarter. 80.56% of the stock is owned by hedge funds and other institutional investors.
Abeona Therapeutics Company Profile
(
Get Free Report)
Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company's research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.
The company's lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
